Overview


According to FutureWise analysis the market for becker muscular dystropy is expected to register a CAGR of 5.22% from 2023-2031.

Becker muscular dystropy (BMD) causes progressive weakness and wasting of the skeletal and cardiac muscles. The disease primarily affects males. A variety of factors can affect the onset and progression of the disease. Between the ages of 5 and 15, muscle weakness usually becomes apparent. First signs of heart disease (cardiomyopathy) can occur in some cases. Furthermore, BMD is caused by a mutation in the DMD gene and is inherited as an X-linked recessive trait. The symptoms of BMD are very similar to those of Duchenne muscular dystrophy, except that they appear later and progress more slowly. Although there is no cure for this condition, ongoing research shows significant promise for treating it. Muscular dystrophy refers to a group of genetic diseases that cause muscle weakness. Muscle building is impeded by genetic mutations that interfere with dystrophin production, which is an essential muscle protein. Symptoms of the disorder include weakening of the heart muscles, breathing problems, and breathing problems.

One of the major factors driving the growth of Becker muscular dystrophy treatment market is the increase in incidences of various types of muscular dystrophy conditions among consumers worldwide. As disease-modifying therapies replace unmet medical needs among patients who are not amenable to mutation-specific drugs, and robust pipelines for developing newer treatments accelerate market growth. A further influence on the market is the development of new treatments, therapies, and treatments coupled with the advancement of treatments and therapies and the increase in awareness of the disorder. The Becker muscular dystrophy treatment market is also positively affected by public awareness about diseases and treatment options, improved healthcare infrastructure, increased investment, and an increase in healthcare spending. Genetically, Becker muscular dystrophy (BMD) follows an X-linked recessive inheritance pattern. People who suffer from this disease lose cardiac and skeletal muscles and become weaker over time. Recessive inheritance makes this disease more likely to affect men than women. This condition causes weakness in the muscles and is known as Becker muscular dystrophy (BMD). There is a fault in a gene called dystrophin that causes this genetic condition. It is also genetically linked to Duchenne muscular dystrophy (DMD), a more severe form of muscle weakness. As compared to DMD, muscle weakness in BMD is less severe and the disease progresses more slowly.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Becker Muscular Dystropy Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Becker Muscular Dystropy Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Italfarmaco Spa
  • Milo Biotechnology lLC
  • Therapeutics Inc
  • Reveragen Biopharma Inc
  • Sarepta Therapeutics Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Diagnosis

  • Blood tests
  • Muscle Biopsy
  • Electromyogram
  • Electrocardiogram
  • Others

By Treatment

  • Assistive Devices
  • Genetic Counseling
  • Medicines
  • Rehabilitation Therapies
  • Surgery

By End-User

  • Hospital
  • Clinic
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Becker Muscular Dystropy Market By Diagnosis, By Treatment, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Becker Muscular Dystropy Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Becker Muscular Dystropy Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Becker Muscular Dystropy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Becker Muscular Dystropy Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Blood tests
        2. Muscle Biopsy
        3. Electromyogram
        4. Electrocardiogram
        5. Others

  • 8.   Becker Muscular Dystropy Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Assistive Devices
        2. Genetic Counseling
        3. Medicines
        4. Rehabilitation Therapies
        5. Surgery

  • 9.   Becker Muscular Dystropy Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital
        2. Clinic
        3. Others

  • 10.   North America Becker Muscular Dystropy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Becker Muscular Dystropy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Becker Muscular Dystropy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Becker Muscular Dystropy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Italfarmaco Spa
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Milo Biotechnology lLC
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Therapeutics Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Reveragen Biopharma Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Sarepta Therapeutics Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients